EXTENDED REPORT

Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems

P Härle*, R H Straub*, R Wiest, A Mayer, J Schölmerich, F Atzeni, M Carrabba, M Cutolo, P Sarzi-Puttini

Objective: To study in parallel the outflow of the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis tone in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Methods: 32 patients with SLE, 62 with RA, and 65 healthy subjects (HS) were included. To measure the tone of the HPA axis, plasma ACTH and serum cortisol were determined. Serum neuropeptide Y (NPY) was used to evaluate the sympathetic outflow.

Results: Patients with SLE had increased NPY levels in comparison with HS, irrespective of prior prednisolone treatment (p<0.001). For patients with RA, only those with prednisolone treatment had increased NPY levels in comparison with HS (p=0.016). Daily prednisolone dose correlated positively with serum NPY in RA (R_{spear}=0.356, p=0.039). In contrast, plasma ACTH levels were generally decreased significantly in comparison with HS in SLE with prednisolone, and in RA with/without prednisolone. Similarly, serum cortisol levels were also decreased in SLE with/without prednisolone, and in RA with prednisolone. The NPY/ACTH ratio was increased in SLE and RA, irrespective of prior prednisolone treatment. The NPY/cortisol ratio was increased in SLE with/without prednisolone, and in RA with prednisolone. Twelve weeks’ anti-TNF antibody treatment with adalimumab did not decrease NPY levels in RA, irrespective of prednisolone treatment.

Conclusions: An increased outflow of the SNS was shown and a decreased tone of the HPA axis in patients with SLE and RA. Low levels of cortisol in relation to SNS neurotransmitters may be proinflammatory because cooperative anti-inflammatory coupling of the two endogenous response axes is missing.

Why might it be important that the activity of the HPA axis and the SNS are up-regulated in parallel, and what would happen if uncoupling of these axes appears? Release of cortisol is typically coupled to release of norepinephrine, which leads to stronger signalling through the β adrenoceptor; several studies have shown cooperation of cortisol and norepinephrine at a molecular level.22–29 This permissive effect of cortisol is due to β adrenoceptor up regulation and stabilisation of the cyclic AMP (cAMP)/protein kinase A/cAMP responsive element binding protein signalling pathway.30 In patients with asthma, this has led to a more effective combination treatment with local glucocorticoids and local β adrenergic agents than either substance alone.31,32 Thus, it seems that instant coupling of the two stress axes and their mediators is important for cooperative effects. Cooperation may be important in chronic inflammatory diseases to efficiently down regulate inflammation in the periphery.33

Abbreviations: ACR, American College of Rheumatology; ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; HPA, hypothalamic-pituitary-adrenal; HS, healthy subjects; IL, interleukin; NPY, neuropeptide Y; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index; SNS, sympathetic nervous system; TNF, tumour necrosis factor

*These authors contributed equally.
This study aimed at investigate the tone of the SNS in patients with SLE and RA by using neuropeptide Y (NPY), the relatively stable sympathetic co-transmitter of norepinephrine. NPY is an excellent indicator of sympathetic activity, which is more stable and has a significantly longer half life in plasma. The correlation between NPY and norepinephrine release has been demonstrated in obstructive sleep apnoea syndrome, experimental stress, hypertension, surgery, hypoxia, and exercise. It is important to mention that the characteristics of norepinephrine and NPY release are not always identical: Norepinephrine is released at low exercise levels, whereas NPY is released at higher exercise levels. This reflects the differential release of norepinephrine and NPY from nerve terminals because norepinephrine is released at low stimulation frequencies, whereas norepinephrine and NPY are released together at higher stimulation frequencies. Furthermore, because NPY is produced in the sympathetic neurone in paravertebral ganglia it needs to be transported to the peripheral nerve ending. Thus, the availability of NPY, in contrast with locally produced norepinephrine, depends on production in the neuronal soma and the transport rate. However, when NPY is increased its most important source is the sympathetic nerve terminal.

To our knowledge, NPY has never been investigated in the serum or plasma of patients with RA and SLE. In parallel with the SNS, we studied the HPA axis tone focusing on ACTH and cortisol. Because administration of prednisolone to healthy subjects increases the SNS tone, we analysed separately patients with and without prior prednisolone treatment. Furthermore, in patients with RA, we investigated the effect of 12 weeks of anti-tumour necrosis factor (TNF) treatment with adalimumab on NPY serum levels.

PATIENTS AND METHODS

Patients, anti-TNF treatment, and healthy subjects
We enrolled 32 white patients with SLE according to the criteria of the American College of Rheumatology (ACR). Clinical activity in these patients was assessed by the SLE Disease Activity Index (SLEDAI). To study patients with another chronic inflammatory disease simultaneously, we included 62 white patients with diagnosed RA fulfilling the ACR criteria. Clinical variables of disease activity included the number of swollen and tender joints and erythrocyte sedimentation rate. Table 1 shows the basic characteristics of both disease groups, including their treatment. None of the patients without prednisolone received glucocorticoids during a period of 6 months before study entry, whereas patients with prednisolone had stable treatment over several weeks before study entry.

Some patients with RA (16 with and 16 without parallel prednisolone) were treated with adalimumab (Abbott SpA, Campoverde di Aprilia, Italy) according to the inclusion criteria of the adalimumab Research in Active RA study (ReAct). These patients with RA received additional methotrexate (stable throughout this study) but no other immunosuppressive drugs. Patients were assigned to receive single self injections of adalimumab 40 mg subcutaneously every other week. Efficacy assessments demonstrated excellent response according to ACR and EULAR response criteria (data not shown; see Atzeni et al45). A baseline, blood sample was taken 1–2 weeks before the start of adalimumab treatment. Anti-TNF antibodies were infused on weeks 0, 2, 4, 6, 8, 10, and 12. These patients were clinically investigated and blood was drawn at baseline, and at weeks 2, 6, and 12.

For comparison, 65 white healthy subjects (HS) were recruited, and their health status verified by a 33 item questionnaire, as previously described.46 Fertile women (HS and patients) were not taking contraceptives and were in the early to mid-follicular phase of the menstrual cycle. Owing to the different ages and sex distribution in the disease groups, subgroup analyses were carried out in order to compare the different groups of patients with HS. The subgroups were matched according to age and sex (table 1). Because serum levels of adrenal hormones are largely independent of sex, male and female subjects were not further separated into subgroups.

The study was approved by the ethics committee of the University Hospital of Regensburg, Germany, and for the adalimumab study, approval was obtained from the ethics committee of I. Sacco University Hospital, Italy.

Laboratory variables
In all subjects, blood was drawn between 08:00 and 10:00 in the morning when the patients visited the outpatient clinic. The blood was immediately centrifuged and serum or plasma was stored at −80°C. We used radioimmunometric assays for the quantitative determination of serum levels of NPY (Euro-Diagnostica AB, Malmö, Sweden, via IBL, Hamburg, Sweden).

Table 1 Basic characteristics of healthy subjects and patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SLE</th>
<th>HS (match SLE)</th>
<th>RA</th>
<th>HS (match RA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>32</td>
<td>42</td>
<td>62</td>
<td>23</td>
</tr>
<tr>
<td>Age (years)</td>
<td>38.1 (2.1)</td>
<td>37.1 (1.5)</td>
<td>57.7 (1.7)</td>
<td>51.5 (0.8)</td>
</tr>
<tr>
<td>Sex, female/male (%)</td>
<td>24/8 (75/25)</td>
<td>25/17 (60/40)</td>
<td>52/10 (84/16)</td>
<td>12/11 (52/48)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8.0 (1.5)</td>
<td>NA</td>
<td>9.7 (1.0)</td>
<td>NA</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>10.9 (1.5)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tender joints</td>
<td>NA</td>
<td>NA</td>
<td>9.0 (0.6)</td>
<td>NA</td>
</tr>
<tr>
<td>Swollen joints</td>
<td>NA</td>
<td>NA</td>
<td>7.5 (0.6)</td>
<td>NA</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>25.0 (3.3)</td>
<td>NA</td>
<td>27.7 (2.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisolone, No (%)</td>
<td>20 (63)</td>
<td>NA</td>
<td>34 (55)</td>
<td>NA</td>
</tr>
<tr>
<td>Prednisolone/day (mg)</td>
<td>9.4 (3.4)</td>
<td>NA</td>
<td>4.3 (0.9)</td>
<td>NA</td>
</tr>
<tr>
<td>NSAID, No (%)</td>
<td>13 (41)</td>
<td>NA</td>
<td>38 (62)</td>
<td>NA</td>
</tr>
<tr>
<td>Methotrexate, No (%)</td>
<td>2 (6)</td>
<td>NA</td>
<td>43 (69)</td>
<td>NA</td>
</tr>
<tr>
<td>Azathioprine, No (%)</td>
<td>12 (38)</td>
<td>NA</td>
<td>0 (0)</td>
<td>NA</td>
</tr>
<tr>
<td>Anti-TNF treatment, No (%)</td>
<td>0 (0)</td>
<td>NA</td>
<td>38 (61)</td>
<td>NA</td>
</tr>
<tr>
<td>Leflunomide, No (%)</td>
<td>0 (0)</td>
<td>NA</td>
<td>8 (13)</td>
<td>NA</td>
</tr>
<tr>
<td>Cyclophosphamide, No (%)</td>
<td>2 (6)</td>
<td>NA</td>
<td>0 (0)</td>
<td>NA</td>
</tr>
<tr>
<td>Hydroxychloroquine, No (%)</td>
<td>3 (9)</td>
<td>NA</td>
<td>4 (6)</td>
<td>NA</td>
</tr>
<tr>
<td>Sulfasalazine, No (%)</td>
<td>0 (0)</td>
<td>NA</td>
<td>2 (3)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Data are given as means (SEM) unless stated otherwise. ESR, erythrocyte sedimentation rate; NA, not applicable; NM, not measured; SLEDAI, SLE Disease Activity Index.
Sympathetic tone/HPA axis activity in SLE and RA

RESULTS

NPY serum levels in patients with SLE, RA, and in HS

Figure 1 demonstrates higher NPY serum levels in patients with SLE than in HS, irrespective of prednisolone treatment (fig 1A). In RA, only patients with prior prednisolone had increased NPY serum levels in comparison with healthy subjects (fig 1B). Because age matched healthy subjects had relatively high NPY serum levels, no difference was noted in comparison with patients with RA without prednisolone treatment (fig 1B).

The results of increased NPY levels in patients with RA treated with prednisolone prompted us to study the interrelation of the daily prednisolone dose and NPY serum levels. Clearly, the prednisolone dose correlated with NPY serum levels in patients with RA but not in patients with SLE (figs 1C and D). However, plasma NPY levels did not correlate with typical markers of disease activity such as tender joint score in RA (without prednisolone: \( R_{\text{rank}} = 0.111, \) NS; with prednisolone: \( R_{\text{rank}} = 0.227, \) NS), swollen joint score in RA (without prednisolone: \( R_{\text{rank}} = -0.010, \) NS; with prednisolone: \( R_{\text{rank}} = 0.356, p = 0.088), and SLEDAI in SLE (without prednisolone: \( R_{\text{rank}} = 0.023, \) NS; with prednisolone: \( R_{\text{rank}} = 0.044, \) NS).

Plasma NPY levels did not differ between male and female patients with or without prednisolone (data not shown). Therapeutic agents such as non-steroidal anti-inflammatory drugs, methotrexate, azathioprine, and leflunomide did not

Presentation of data and statistical analysis

The data are given as box plots with the 5th, 10th, 50th (median), 90th, and 95th centiles. Group medians were compared by the non-parametric Mann-Whitney test, correlations were calculated by Spearman rank correlation analysis (SPSS/PC, version 11.5, SPSS Inc, Chicago, USA). A decrease or increase of a variable over time (during adalimumab treatment) was tested by the non-parametric Friedman test (SPSS). A value of \( p < 0.05 \) was the level of significance.

Figure 1  Serum NPY in HS, patients with SLE and RA. (A) Comparison of HS and patients with SLE. (B) Comparison of HS and patients with RA. For panels (A) and (B) data are given as box plots with the 5th, 10th, 50th (median), 90th, and 95th centiles. (C) and (D) Interrelation of daily prednisolone dose and serum NPY levels in prednisolone treated patients with SLE (C) and RA (D). The linear regression line, the rank correlation coefficient and its p value are given.

Figure 2 Relation of NPY and plasma ACTH in HS, patients with SLE, and RA. [A] and [B] Plasma levels of ACTH. [C] and [D] Ratio of serum NPY and plasma ACTH. All data are given as box plots with the 5th, 10th, 50th (median), 90th, and 95th centiles.

Germany; detection limit: 6 pmol/l). Although the behaviour of plasma ACTH and serum cortisol is known in patients with SLE and RA, we measured these hormones to calculate ratios of serum NPY/plasma ACTH and serum NPY/serum cortisol. These ratios should give an impression of the interrelation of the two hormones included. We used a radioimmunometric assay for the quantitative determination of serum levels of cortisol (Coulter Immunotech, Marseilles, France, via IBL; detection limit: 10 nmol/l) and an enzyme immunoassay to detect plasma ACTH (Sangui BioTech, Inc, California, USA, via IBL; detection limit: 0.1 pmol/l). For all assays, intra-assay and interassay coefficients of variation were below 10%.
patients (fig 3C). In RA, only patients with prior prednisolone had a higher increased ratio of NPY/cortisol than untreated patients. Additionally, patients with SLE treated with prednisolone demonstrated a preponderance of the SNS over the HPA axis even in healthy subjects. Interestingly, 12 weeks of anti-TNF treatment in patients with RA slightly reduced serum NPY levels in comparison with HS (fig 3D). The above-mentioned ratios did not differ between male and female patients with or without prednisolone (data not shown). Therapeutic agents such as non-steroidal anti-inflammatory drugs, methotrexate, azathioprine, and leflunomide did not influence serum NPY levels in patients with RA or SLE (data not shown).

**Relation of NPY serum levels and HPA axis hormones**

To study the relation between NPY and HPA axis hormones, molar ratios of NPY/ACTH and NPY/cortisol were calculated. These ratios express a possible preponderance of the SNS over the HPA axis or vice versa. As expected, patients with SLE and RA with prior prednisolone demonstrated decreased ACTH levels (figs 2A and B). In addition, patients with RA without prior prednisolone treatment also had decreased ACTH levels in comparison with healthy subjects (fig 2B). The ratio of NPY/ACTH was significantly higher in patients with SLE and RA than in healthy controls, irrespective of prior prednisolone treatment (figs 2C and D). In patients with RA, prednisolone treatment increased this particular ratio (fig 2D).

For cortisol, patients with SLE demonstrated decreased serum levels, irrespective of prior prednisolone treatment (fig 3A). In RA, only those patients with prior prednisolone treatment had decreased cortisol serum levels (fig 3B). The ratio of NPY/cortisol was increased in both SLE patient groups, irrespective of prednisolone treatment (fig 3C). Additionally, patients with SLE treated with prednisolone had a higher increased ratio of NPY/cortisol than untreated patients (fig 3C). In RA, only patients with prior prednisolone treatment had an increased ratio of NPY/cortisol in comparison with HS (fig 3D).

The influence of anti-TNF treatment in RA on NPY serum levels

Using the Friedman test statistics, 12 weeks of anti-TNF treatment did not change NPY serum levels, irrespective of prednisolone treatment (fig 4). Again it is obvious that patients with RA with prednisolone had increased serum NPY levels in comparison with untreated patients with RA (fig 4). In addition, neither the ratio of serum NPY/plasma ACTH nor the ratio of serum NPY/serum cortisol changed during 12 weeks of anti-TNF treatment (data not shown).

**DISCUSSION**

Using NPY as a reliable read-out measure of the SNS activity, we were able to demonstrate an increased SNS outflow in relation to the HPA axis tone in all patients with SLE and in patients with RA treated with prednisolone. For the ratio of serum NPY/plasma ACTH, also patients with RA without prednisolone demonstrated a preponderance of the SNS over the HPA axis.

Several studies have demonstrated an increased sympathetic tone in patients with chronic inflammatory diseases. However, none of these studies investigated the tone of the HPA axis in parallel. Thus, the preponderance of one system over the other was not investigated. In a recent study in patients with Crohn’s disease and ulcerative colitis, we observed a very similar phenomenon of a preponderance of the SNS over the HPA axis: serum NPY levels were increased, whereas serum cortisol levels were normal or decreased. We called this phenomenon uncoupling of the SNS and HPA axis in order to emphasise the loss of cooperative activities of these two endogenous response systems. This present study supports uncoupling of the two main response axes in patients with SLE and RA. Uncoupling is enhanced in prednisolone treated patients because prednisolone stimulates the SNS and inhibits the HPA axis even in healthy subjects. Interestingly, 12 weeks of anti-TNF treatment in patients with RA slightly reduced raised NPY serum levels and SNS dominance. Thus, it seems
that uncoupling is enduringly imprinted, and it is obvious that TNF is not the sole and main factor responsible for this phenomenon.

For patients without prednisolone treatment, it is interesting that the uncoupling phenomenon is obvious in our young patients with SLE but not similarly in the older patients with RA. Similarly, our recent studies in young patients with inflammatory bowel disease demonstrated the uncoupling phenomenon in patients without prednisolone.44 It may well be that aging has an influence on the uncoupling phenomenon, which has been demonstrated in HS focusing on serum cortisol and plasma norepinephrine.45 In this latter study, however, plasma NPY levels did not similarly increase during aging, which was shown for plasma norepinephrine, confirming an earlier study.45 Thus, it seems that in older subjects NPY is not produced to a similar extent as norepinephrine.46 From this point of view, it may well be that older patients with RA without prednisolone do not demonstrate high levels of NPY, though norepinephrine might have been increased. In older patients, NPY may not be the ideal measure when SNS activity is only increased to a small extent. In our study we did not measure norepinephrine because we expected a strong bias due to a prolonged storage period (norepinephrine is much more labile than NPY).

Coupling of the SNS and HPA axis is important because it supports the β adrenergic and glucocorticoid receptor pathways,24–26 which would lead to stronger cooperative effects than using one system alone. Cooperative activity of both axes is observed in asthmatic patients who use local glucocorticoids and local β2 adrenergic agents.32,33 In these patients, cooperation increases the bronchodilatory effect of each substance alone. A similar cooperation can be observed in patients with septic shock: combined treatment with norepinephrine and cortisol leads to improved circulation and blood pressure. Similarly, a cooperative effect of cortisol and norepinephrine is also found in patients with RA (see below).

In patients with chronic inflammatory diseases, a relative loss of HPA axis hormones in relation to proinflammatory cytokines may lead to deficient vasopressive activity of SNS neurotransmitters, which may consequently lead to up regulation of the SNS tone. This may counterbalance the loss of cortisol in the presence of increased circulating vasodilators such as nitric oxide, TNF, and others. These SNS changes may be supported by the observed hypothalamic shift from initially high CRH expression to chronically increased vasopressin expression, which has been demonstrated during experimental arthritis.47 This shift to increased vasopressin production can also be viewed as a sign of an increased sympathetic tone in relation to the HPA axis (CRH) because increased vasopressin levels would support the SNS in stabilising blood pressure. Apart from effects on bronchodilation and circulation, cooperation may also lead to stronger anti-inflammatory effects. In addition, disease related factors such as depression, chronic pain, weight gain, and others may add to the uncoupling phenomenon.

In patients with RA, we recently demonstrated anti-inflammatory cooperation of norepinephrine and cortisol:31 combined administration of norepinephrine and cortisol to cultured mixed synovial cells led to a stronger reduction of TNF, IL-8, and IL-6 secretion than the use of each substance alone. Furthermore, patients with RA with prednisolone treatment and presence of synovial sympathetic nerve fibres had decreased histological markers of synovial inflammation in comparison with patients without prednisolone treatment or without sympathetic innervation.31 Thus, high levels of mediators of the SNS together with cortisol at the local site of inflammation may be favourable factors which dampen inflammation. However, it has been demonstrated that sympathetic innervation is decreased in inflammatory processes such as in the spleen of lupus lpr/lpr mice,31 in the synovium of patients with RA,25 and in inflamed islets of diabetic rats.25 Thus, an increased systemic tone of the SNS probably would not lead to increased local sympathetic neurotransmitters because sympathetic nerve fibres are lost. In such a situation, local concentrations of sympathetic neurotransmitters are low, which would support the proinflammatory process via α adrenoreceptors (reviewed by Straub et al48). Loss of sympathetic nerve fibres and low levels of cortisol and androgens would lead to a proinflammatory microenvironment in inflamed tissue. In support of this notion, it has been repeatedly demonstrated that a higher SNS tone increases circulating leucocytes, such as monocytes, NK cells, and neutrophils.45,46 Probably, this has been evolutionarily conserved in order to support the immune system in the very early phase of a systemic inflammatory response (help for the innate immune system). However, in patients with chronic inflammatory diseases such a stimulation of leucocyte migration and redistribution is probably unfavourable.

In conclusion, an increased SNS tone in the presence of a defective HPA axis probably supports the continuing inflammatory process. In addition, an increased SNS tone would support atherosclerosis in patients with chronic inflammatory diseases. These observations may stimulate rheumatologists to treat patients with centrally acting drugs in order to inhibit enhanced SNS outflow.

ACKNOWLEDGEMENTS

We thank Angelika Gräber and Melanie Grünbeck for excellent technical assistance.

Authors’ affiliations

P Härle, R H Straub, R Wiest, A Mayer, J Schölmerich, Laboratory of Neuroendocrineimmunology, Department of Internal Medicine I, University Hospital Regensburg, Germany

F Atzeni, M Carabba, P Sarzi-Puttini, Rheumatology Unit, University Hospital L Sacco, Milan, Italy

M Cutolo, Division of Rheumatology, Department of Internal Medicine and Medical Specialties, University of Genova, Italy

REFERENCES


Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems

P Härlé, R H Straub, R Wiest, A Mayer, J Schölmerich, F Atzeni, M Carrabba, M Cutolo and P Sarzi-Puttini

Ann Rheum Dis 2006 65: 51-56 originally published online June 7, 2005
doi: 10.1136/ard.2005.038059

Updated information and services can be found at:
http://ard.bmj.com/content/65/1/51

These include:

References
This article cites 54 articles, 11 of which you can access for free at:
http://ard.bmj.com/content/65/1/51#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Immunology (including allergy) (5144)
Systemic lupus erythematosus (571)
Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)
Biological agents (545)
Drugs: musculoskeletal and joint diseases (700)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/